Polycystic ovary syndrome and nonalcoholic fatty liver disease

Amna Subhan Butt; Jalpa Devi

doi:10.1016/B978-0-323-87932-3.00021-9

Polycystic ovary syndrome and nonalcoholic fatty liver disease

Amna Subhan Butt, Jalpa Devi

Section of Gastroenterology, Department of Medicine, Medical College, Pakistan

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Polycystic ovary syndrome (PCOS) is an endocrine and metabolic dysfunction ranging from 6% to 20% among premenopausal females that imposes a huge healthcare burden worldwide. A strong association has been reported between markers of metabolic dysfunction such as visceral obesity and insulin resistance with both PCOS and nonalcoholic fatty liver disease (NAFLD). Different studies showed the prevalence of NAFLD among PCOS females ranging from 34% to 70%, which is higher than the general population, and this points toward some association between both these entities. Attributed to underlying metabolic syndrome, both NAFLD and PCOS have been reported to be associated with higher morbidity and mortality. This chapter aims to review the various aspects of the link between PCOS and NAFLD.

Original language	English
Title of host publication	Polycystic Ovary Syndrome
Subtitle of host publication	Basic Science to Clinical Advances across the Lifespan
Publisher	Elsevier
Pages	92-99
Number of pages	8
ISBN (Electronic)	9780323879323
ISBN (Print)	9780323879330
DOIs	https://doi.org/10.1016/B978-0-323-87932-3.00021-9
Publication status	Published - 1 Jan 2023

Keywords

cirrhosis
metabolic syndrome
NAFLD
NASH
nonalcoholic fatty liver disease
PCOS
Polycystic ovary syndrome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-323-87932-3.00021-9

Cite this

@inbook{76d7a6a8d61c4d069ba0024f53ee6a20,

title = "Polycystic ovary syndrome and nonalcoholic fatty liver disease",

abstract = "Polycystic ovary syndrome (PCOS) is an endocrine and metabolic dysfunction ranging from 6% to 20% among premenopausal females that imposes a huge healthcare burden worldwide. A strong association has been reported between markers of metabolic dysfunction such as visceral obesity and insulin resistance with both PCOS and nonalcoholic fatty liver disease (NAFLD). Different studies showed the prevalence of NAFLD among PCOS females ranging from 34% to 70%, which is higher than the general population, and this points toward some association between both these entities. Attributed to underlying metabolic syndrome, both NAFLD and PCOS have been reported to be associated with higher morbidity and mortality. This chapter aims to review the various aspects of the link between PCOS and NAFLD.",

keywords = "cirrhosis, metabolic syndrome, NAFLD, NASH, nonalcoholic fatty liver disease, PCOS, Polycystic ovary syndrome",

author = "Butt, {Amna Subhan} and Jalpa Devi",

year = "2023",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-87932-3.00021-9",

language = "English",

isbn = "9780323879330",

pages = "92--99",

booktitle = "Polycystic Ovary Syndrome",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Polycystic ovary syndrome and nonalcoholic fatty liver disease

AU - Butt, Amna Subhan

AU - Devi, Jalpa

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Polycystic ovary syndrome (PCOS) is an endocrine and metabolic dysfunction ranging from 6% to 20% among premenopausal females that imposes a huge healthcare burden worldwide. A strong association has been reported between markers of metabolic dysfunction such as visceral obesity and insulin resistance with both PCOS and nonalcoholic fatty liver disease (NAFLD). Different studies showed the prevalence of NAFLD among PCOS females ranging from 34% to 70%, which is higher than the general population, and this points toward some association between both these entities. Attributed to underlying metabolic syndrome, both NAFLD and PCOS have been reported to be associated with higher morbidity and mortality. This chapter aims to review the various aspects of the link between PCOS and NAFLD.

AB - Polycystic ovary syndrome (PCOS) is an endocrine and metabolic dysfunction ranging from 6% to 20% among premenopausal females that imposes a huge healthcare burden worldwide. A strong association has been reported between markers of metabolic dysfunction such as visceral obesity and insulin resistance with both PCOS and nonalcoholic fatty liver disease (NAFLD). Different studies showed the prevalence of NAFLD among PCOS females ranging from 34% to 70%, which is higher than the general population, and this points toward some association between both these entities. Attributed to underlying metabolic syndrome, both NAFLD and PCOS have been reported to be associated with higher morbidity and mortality. This chapter aims to review the various aspects of the link between PCOS and NAFLD.

KW - cirrhosis

KW - metabolic syndrome

KW - NAFLD

KW - NASH

KW - nonalcoholic fatty liver disease

KW - PCOS

KW - Polycystic ovary syndrome

UR - http://www.scopus.com/inward/record.url?scp=85160128694&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-87932-3.00021-9

DO - 10.1016/B978-0-323-87932-3.00021-9

M3 - Chapter

AN - SCOPUS:85160128694

SN - 9780323879330

SP - 92

EP - 99

BT - Polycystic Ovary Syndrome

PB - Elsevier

ER -

Polycystic ovary syndrome and nonalcoholic fatty liver disease

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this